Department of Surgery, Emory University, Atlanta, GA 30322, USA.
J Am Coll Surg. 2012 Apr;214(4):400-7; discussion 407-8. doi: 10.1016/j.jamcollsurg.2011.12.046.
Severe secondary hyperparathyroidism, which is associated with life-threatening complications, can develop in dialysis-dependent end-stage renal disease patients. The aim of this study was to compare short- and long-term mortality in dialysis patients who underwent near-total parathyroidectomy (NTPTX) and matched nonoperated controls.
We identified 150 dialysis patients who underwent NTPTX (1993-2009) at our institution and compared them with 1,044 nonoperated control patients identified in the US Renal Data System registry, matched for age, sex, race, diabetes as cause of kidney failure, years on dialysis, and dialysis modality. Survival outcomes were estimated using multivariable Cox proportional hazards models with stratification on the matching sets, adjusted for cardiovascular comorbidities, smoking, inability to ambulate/transfer, and payor status.
During a follow-up of a mean of 3.6 years (range 0.1 month to 16.4 years), NTPTX patients had a significant reduction in the long-term risk of all-cause death (hazard ratio = 0.68; 95% CI, 0.52-0.89; p = 0.006) compared with controls. Thirty-day mortality rates for NTPTX patients and controls were 246 vs 105 per 1,000 person-years (p = 0.21). In adjusted analyses, NTPTX patients had a 37% reduced risk of all-cause death and a 33% reduced risk of cardiovascular death compared with controls. A durable reduction in mean parathyroid hormone was observed after NTPTX; from 1,776 ± 1,416.6 pg/mL to 301 ± 285.7 pg/mL (p < 0.0001).
In our center, NTPTX in dialysis patients was associated with a significant reduction in long-term risk of death compared with matched control patients, without a significantly increased short-term risk.
在依赖透析的终末期肾病患者中,可发生危及生命的严重继发性甲状旁腺功能亢进症。本研究的目的是比较接受甲状旁腺全切除术(NTPTX)和匹配的未手术对照组透析患者的短期和长期死亡率。
我们确定了在我院接受 NTPTX(1993-2009 年)的 150 例透析患者,并与在美国肾脏数据系统登记处确定的 1044 例未手术对照患者进行比较,这些患者按年龄、性别、种族、肾衰竭病因(糖尿病)、透析年限和透析方式进行匹配。使用多变量 Cox 比例风险模型估计生存结果,并对匹配组进行分层,调整心血管合并症、吸烟、无法行走/转移和支付者状态。
在平均 3.6 年(0.1 个月至 16.4 年)的随访期间,与对照组相比,NTPTX 患者全因死亡的长期风险显著降低(风险比=0.68;95%CI,0.52-0.89;p=0.006)。NTPTX 患者和对照组的 30 天死亡率分别为每 1000 人年 246 例和 105 例(p=0.21)。在调整后的分析中,与对照组相比,NTPTX 患者全因死亡风险降低 37%,心血管死亡风险降低 33%。NTPTX 后甲状旁腺激素的均值持续降低;从 1776±1416.6 pg/mL 降至 301±285.7 pg/mL(p<0.0001)。
在我们的中心,与匹配的对照组患者相比,透析患者接受 NTPTX 与长期死亡风险显著降低相关,而短期风险无显著增加。